¼¼°èÀÇ ÀÇ·á±â±â RA ½ÃÀå
Medical Device Regulatory Affairs
»óǰÄÚµå : 1782875
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 380 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÇ·á±â±â RA ¼¼°è ½ÃÀåÀº 2030³â±îÁö 210¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 131¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÇ·á±â±â RA ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 8.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 210¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±ÔÁ¦ ÄÁ¼³ÆÃÀº CAGR 9.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 75¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ýÀû ´ë¸® ¾÷¹«ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 6.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 36¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÇ·á±â±â RA ½ÃÀåÀº 2024³â¿¡ 36¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 46¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 4.0%¿Í 7.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÇ·á±â±â RA ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö RA°¡ ÀÇ·á±â±â »ó¾÷È­ÀÇ Áß½ÉÀÌ µÇ°í Àִ°¡?

ºü¸£°Ô º¯È­ÇÏ´Â ¿À´Ã³¯ÀÇ ÇコÄɾî ȯ°æ¿¡¼­ ¾à»ç ¾÷¹«´Â ÀÇ·á±â±â »ê¾÷¿¡¼­ Àü·«Àû ¿äÃæÁö·Î¼­, Á¦Ç°ÀÌ ½ÃÀå ½ÂÀο¡ ÇÊ¿äÇÑ ¾ö°ÝÇÑ ¾ÈÀü¼º, À¯È¿¼º ¹× ¼º´É ±âÁØÀ» ÃæÁ·ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á±â±â°¡ Á¡Á¡ ´õ º¹ÀâÇØÁö°í, ¸¹Àº °æ¿ì ¼ÒÇÁÆ®¿þ¾î, µðÁöÅÐ ¿¬°á, AI°¡ ÅëÇյǾî Àֱ⠶§¹®¿¡ ¾à»ç ½ÂÀÎ ÀýÂ÷µµ ±×¿¡ µû¶ó º¹ÀâÇØÁö°í ½Ã°£ÀÌ ¿À·¡ °É¸®°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ½ÃÆÇ Àü ½Åû, Á¦Ç° ºÐ·ù, À§Çè °ü¸® ÇÁ·ÎÅäÄÝ, ½ÃÆÇ ÈÄ Á¶»ç ¿ä°ÇÀ» ¿øÈ°ÇÏ°Ô ÁøÇàÇϱâ À§ÇØ ¾à»ç Àü¹® ÆÀ¿¡ ´ëÇÑ ÅõÀÚ¿Í Àü¹® Áö½ÄÀÇ ¾Æ¿ô¼Ò½ÌÀ» Á¡Á¡ ´õ ¸¹ÀÌ ÁøÇàÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ FDA, À¯·´ÀǾàǰû(EMA), ÀϺ» ÀǾàǰÀÇ·á±â±âÁ¾Çձⱸ(PMDA), Áß±¹ ÀǾàǰÀÇ·á±â±âÁ¾Çձⱸ(NMPA) µî ±ÔÁ¦±â°üÀº ±â¼ú Çõ½Å¿¡ ´ëÀÀÇϱâ À§ÇØ Áö¼ÓÀûÀ¸·Î ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¸¦ ¾÷µ¥ÀÌÆ®Çϰí ÀÖ½À´Ï´Ù. EU ÀÇ·á±â±â ±ÔÁ¤(MDR)°ú ü¿ÜÁø´Ü¿ë ÀǾàǰ ±ÔÁ¤(IVDR)°ú °°Àº ÃÖ±Ù ±ÔÁ¤Àº ÀÓ»ó Æò°¡, ±â±â ºÐ·ù, ÃßÀû¼º, ½ÃÆÇ ÈÄ Àǹ«¿¡ ´ëÇÑ º¸´Ù ¾ö°ÝÇÑ ±ÔÁ¤À» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¾à»ç ¾÷¹«¸¦ ¹é¿£µå ÄÄÇöóÀ̾𽺠±â´É¿¡¼­ Á¦Ç° °³¹ßÀÇ Àü·«Àû ÆÄÆ®³Ê·Î º¯È­½ÃÄ×½À´Ï´Ù. ±â¾÷µéÀº ÇöÀç Á¦Ç° ¼ö¸íÁÖ±â Ãʱ⿡ ¾à»ç Àü·«À» ÅëÇÕÇÏ¿© ½ÃÆÇ Áö¿¬, ½ÃÀå ö¼ö, dz¹® ÇÇÇØÀÇ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¼¼°è ÀÇ·á±â±â ½ÃÀåÀÌ »õ·Î¿î Áö¿ªÀ¸·Î È®´ëµÊ¿¡ µû¶ó ±ÔÁ¦ Á¶È­¿Í ÇöÁöÈ­¶ó´Â ÀÌÁßÀÇ °úÁ¦°¡ ´ëµÎµÇ°í ÀÖÀ¸¸ç, ±¹Á¦ Ç¥Áذú ±¹°¡º° ´µ¾Ó½º¿¡ ´ëÇÑ ±íÀº Áö½ÄÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

±â¼ú°ú µ¥ÀÌÅÍ´Â ¾î¶»°Ô ¾àǰ ½ÅûÀÇ ¹Ì·¡¸¦ Çü¼ºÇϰí Àִ°¡?

±â¼úÀº µðÁöÅÐ µµ±¸¿Í µ¥ÀÌÅÍ ±â¹Ý ½Ã½ºÅÛÀ» ÅëÇØ ¾à±¹ ¾÷¹«¸¦ ÀçÆíÇϰí, È¿À²¼º, Á¤È®¼º, ½Åû ¹× ÄÄÇöóÀ̾𽺠Åõ¸í¼ºÀ» Çâ»ó½ÃŰ´Â µðÁöÅÐ µµ±¸¿Í µ¥ÀÌÅÍ ±â¹Ý ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. FDAÀÇ eSTAR³ª EMAÀÇ EUDAMED¿Í °°Àº Ç÷§ÆûÀ» ÅëÇÑ ÀüÀÚ ½ÅûÀº ¼öÀÛ¾÷À¸·Î ÀÛ¼ºµÈ ¹®¼­¸¦ ´ëüÇÏ¿© ¿À·ù¸¦ ÁÙÀ̰í, ŸÀÓ¶óÀÎÀ» °³¼±Çϸç, ±ÔÁ¦ µ¥ÀÌÅÍ¿¡ ´ëÇÑ Á¢±ÙÀ» ¿ëÀÌÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ Á¤º¸ °ü¸® ½Ã½ºÅÛ(RIMS)Àº ½Åû »óÅ ÃßÀû, °¢±¹ÀÇ Á¦Ç° µî·Ï °ü¸®, ±ÔÁ¦ Á¤º¸ µ¥ÀÌÅͺ£À̽ºÀÇ À¯Áö °ü¸®¸¦ À§ÇØ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ¹®¼­ Çü½Ä, ½ÂÀÎ ÀÏÁ¤, °¨½Ã ¿ä°ÇÀÌ ¼­·Î ´Ù¸¥ ¿©·¯ °üÇұǿ¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ±â¾÷¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×Àº ¹®Çå °Ë»ö ÀÚµ¿È­, ºÎÀÛ¿ë ÆÐÅÏ ºÐ¼®, °ú°Å µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÑ ±ÔÁ¦ ¸®½ºÅ© ¿¹Ãø µî ¾à¹« ¾÷¹«¿¡µµ Àû¿ëµÇ±â ½ÃÀÛÇß½À´Ï´Ù. ÀÚ¿¬¾î ó¸®(NLP) µµ±¸´Â ´ë·®ÀÇ ±ÔÁ¦ ´ç±¹ ÅØ½ºÆ®¸¦ ÃßÃâÇϰí Á¤¸®ÇÏ´Â µ¥ »ç¿ëµÇ¸ç, ÆÀÀº Á¦Ãâ Áغñ°¡ ¿Ï·áµÈ ¹®¼­¸¦ º¸´Ù È¿À²ÀûÀ¸·Î ÀÛ¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº ¾à»ç ÆÀ, ÀÓ»ó Àü¹®°¡, ÄÁ¼³ÅÏÆ® °£ÀÇ ¼¼°è Çù¾÷À» ÃËÁøÇϰí, ÀåºñÀÇ Àüü ¼ö¸íÁֱ⠵¿¾È Àϰü¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ÀÇ»ç°áÁ¤¿¡ ÀÖ¾î ¸®¾ó¿ùµå¿¡ºñ´ø½º(RWE)¿Í ¸®¾ó¿ùµåµ¥ÀÌÅÍ(RWD)ÀÇ ÅëÇÕÀÌ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, ±ÔÁ¦ ´ç±¹Àº ½ÃÆÇ ÈÄ ¸ð´ÏÅ͸µ ¹× ½ÂÀÎ ¿¬ÀåÀ» À§ÇØ ÀÌ·¯ÇÑ µ¥ÀÌÅÍ À¯ÇüÀ» ¼ö¿ëÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ¹ßÀüÀº ¾÷¹«¸¦ °£¼ÒÈ­ÇÏ°í ¾à»ç Àü¹®°¡°¡ Á¶Á÷ ³»¿¡¼­ º¸´Ù Àü·«ÀûÀÌ°í ºÐ¼®ÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

´©°¡ ÁÖµµÇϰí, ¼¼°èÈ­°¡ ¾à»ç Àü·«¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

¹æ´ëÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ º¸À¯ÇÑ ´Ù±¹Àû ±â¾÷ºÎÅÍ ÆÄ±«Àû Çõ½ÅÀ» ½ÃÀå¿¡ ³»³õ´Â ½Å»ý ±â¾÷±îÁö ÀÇ·á±â±â »ê¾÷ Àü ºÐ¾ß¿¡ °ÉÃÄ ¾à»ç¹ý ±ÔÁ¦ ½ÃÀåÀÌ ºü¸£°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ´ëÇü ÀÇ·á±â±â ±â¾÷µéÀº ±¤¹üÀ§ÇÑ ÆÄÀÌÇÁ¶óÀΰú ¿©·¯ ½ÃÀå ÁøÀÔÀ» °ü¸®Çϱâ À§ÇØ ¼¼°è Àü¹® Áö½ÄÀ» °®Ãá ¾à»çÆÀÀ» »ç³»¿¡ ±¸ÃàÇϰí ÀÖÁö¸¸, Áß¼ÒÇü ±â¾÷µéÀº Àü¹® ¾à»ç ÄÁ¼³ÅÏÆ®³ª CRO(ÀǾàǰ °³¹ß ¼öʱâ°ü)ÀÇ µµ¿òÀ» ¹Þ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾Æ¿ô¼Ò½ÌÀ¸·ÎÀÇ ÀüȯÀº 510(k), PMA, CE ¸¶Å·, ±â¼úÀÚ·á µîÀÇ Á¦Ãâ¿¡ ¸¹Àº ÀÚ¿ø°ú ½Ã°£ÀÌ ¼Ò¿äµÇ´Â EU³ª ¹Ì±¹°ú °°ÀÌ ±ÔÁ¦°¡ ¾ö°ÝÇÑ ½ÃÀå¿¡¼­ ƯÈ÷ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù.

Á¦Á¶¾÷üµéÀÌ ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ÀÇ °í¼ºÀå ½ÃÀå¿¡ ´ëÇÑ Á¢±ÙÀ» ¸ð»öÇÏ´Â °¡¿îµ¥, ¼¼°èÈ­´Â ±ÔÁ¦ Àü·«¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̵é Áö¿ªÀº ±¹Á¦ ±âÁØ¿¡ ºÎÇÕÇϵµ·Ï ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¸¦ °­È­ÇÏ´Â ÇÑÆí, Áö¿ªÀû ÄÄÇöóÀ̾𽺠¿ä°ÇÀ» À¯ÁöÇϸ鼭 Áö¿ª ƯÀ¯ÀÇ ¹Ì¹¦ÇÑ Á¢±Ù¹æ½ÄÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Áß±¹ÀÇ NMPA ½ÂÀÎ ÀýÂ÷°¡ ÁøÈ­Çϰí ÀÖÀ¸¸ç, ÇöÀç ¸¹Àº ÀÇ·á±â±â¿¡ ÇöÁö ÀÓ»ó µ¥ÀÌÅͰ¡ Àǹ«È­µÇ¾î Àֱ⠶§¹®¿¡ ¿ÜÀÚ±â¾÷Àº ÇöÁö ¹ýÀΰú Çù·ÂÇØ¾ß ÇÕ´Ï´Ù. ÀÌ¿Í º´ÇàÇÏ¿© ±¹Á¦ÀÇ·á±â±â±ÔÁ¦´ç±¹ÀÚÆ÷·³(IMDRF)°ú °°Àº ÀÌ´Ï¼ÅÆ¼ºê´Â Áߺ¹À» ÁÙÀ̰í Àü ¼¼°è ½ÂÀÎÀ» ¿ëÀÌÇÏ°Ô Çϱâ À§ÇØ ½Åû Çü½Ä°ú ¿ë¾îÀÇ Á¶Á¤À» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ±â¾÷µéÀº Áß¾ÓÁýÁßÇü°ú ºÐ»êÇü ½ÃÀå ¸ðµ¨ ¸ðµÎ¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â ¹ÎøÇÏ°í ±¹°æÀ» ÃÊ¿ùÇÑ ´ÜÀ§·Î¼­ ±â´ÉÇÒ ¼ö ÀÖµµ·Ï ¾à¹«ÆÀÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á±â±â RA ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

ÀÇ·á±â±â RA ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ±â¼ú Çõ½Å, ±ÔÁ¦ °­È­, ¼¼°è ÇコÄÉ¾î ½ÃÀå È®´ë¿Í °ü·ÃµÈ ¸î °¡Áö »óÈ£ ¿¬°üµÈ ¿äÀÎÀÔ´Ï´Ù. ¹«¾ùº¸´Ùµµ ÀÇ·á±â±âÀÇ º¹ÀâÈ­, ƯÈ÷ SaMD(¼ÒÇÁÆ®¿þ¾î·Î¼­ÀÇ ÀÇ·á±â±â), AI¸¦ Ȱ¿ëÇÑ Áø´Ü, º¹ÇÕÁ¦Ç° µîÀÇ º¹ÀâÈ­·Î ÀÎÇØ ±ÔÁ¦´ç±¹°úÀÇ ±íÀº °ü¿©¿Í Àû±ØÀûÀÎ Àü·«¼ö¸³ÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺Àº Á¤±âÀûÀÎ ½Åû ±â¹Ý ÄÄÇöóÀ̾𽺿¡¼­ Áö¼ÓÀûÀÎ ¶óÀÌÇÁ»çÀÌŬ ¸ð´ÏÅ͸µÀ¸·ÎÀÇ ÀüȯÀ¸·Î ÀÎÇØ ´õ¿í ÁõÆøµÇ¾î ±â¾÷Àº ¾ÈÀü ½ÅÈ£, ÇöÀå ¼º´É ¹× ¶óº§¸µ ¾÷µ¥ÀÌÆ®¿¡ ´ëÇÑ ½Ç½Ã°£ °æ°è¸¦ À¯ÁöÇØ¾ß ÇÕ´Ï´Ù.

ÃÖÁ¾ ¿ëµµÀÇ ´Ù¾çÈ­µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ ºÐ¾ßÀÇ ½ºÅ¸Æ®¾÷, Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷, ¼ÒºñÀÚ ´ë»ó ÇÏÀÌÅ×Å© ±â¾÷ µî ±âÁ¸°ú´Â ´Ù¸¥ ±â¾÷µéÀÌ ÀÇ·á±â±â ºÐ¾ß¿¡ ÁøÃâÇÔ¿¡ µû¶ó, ³¸¼± ±ÔÁ¦ ȯ°æÀ» ±Øº¹Çϱâ À§ÇØ Àü¹®ÀûÀÎ ±ÔÁ¦ Áö¿øÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Åõ¸í¼º°ú ¾ÈÀü¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ¿ä±¸°¡ ³ô¾ÆÁö°í, ÀÇ·á±â±â ¸®Äݰú ºÎÀÛ¿ë¿¡ ´ëÇÑ ¾ð·ÐÀÇ ÁýÁß Á¶»ç¿Í ¸Â¹°·Á ±â¾÷µéÀº ÄÄÇöóÀÌ¾ð½º¿Í ¸®½ºÅ© Ä¿¹Â´ÏÄÉÀ̼ÇÀ» ºê·£µå ½Å·Ú¼ºÀÇ ÇÙ½ÉÀ¸·Î »ï°í ÀÖ½À´Ï´Ù. ¾÷¹« Ãø¸é¿¡¼­´Â ¿ø°Ý °¨»ç, µðÁöÅÐ ½Åû, AI¸¦ Ȱ¿ëÇÑ ±ÔÁ¦ ±â¼úÀÇ ºÎ»óÀ¸·Î ½ÅûÀÇ Á¤È®¼ºÀÌ Çâ»óµÇ°í ½É»ç ½Ã°£ÀÌ ´ÜÃàµÇ¾î ÅõÀÚ ¼öÀÍ·üÀÌ Çâ»óµÇ¾î µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, Àü ¼¼°èÀûÀ¸·Î ÇコÄÉ¾î ½Ã½ºÅÛÀÌ È®´ëµÇ°í µð¹ÙÀ̽º¸¦ Æ÷ÇÔÇÑ ÀÓ»ó½ÃÇèÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ´Ù¾çÇÑ ºÐ¾ßÀÇ Àü¹®¼ºÀ» °®Ãá ¾à»ç Àü¹®°¡¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº ½ÃÀå¿¡¼­ ¼÷·ÃµÈ ¾à»ç ÀηÂÀÇ ºÎÁ·Àº ¾à»ç ¼­ºñ½º Á¦°ø¾÷ü¿Í ±³À° Ç÷§ÆûÀÇ ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ¾à¹« ¾÷¹«´Â ´Ü¼øÇÑ ÄÄÇöóÀ̾𽺠±â´ÉÀÌ ¾Æ´Ñ ÀÇ·á±â±â Çõ½Å »ýŰ迡¼­ ¼ºÀåÀ» °¡´ÉÇÏ°Ô ÇÏ´Â Áß¿äÇÑ ÈûÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¼­ºñ½º(¾à»ç ÄÁ¼³ÆÃ, ¹ýÀû ´ë¸®, ¾à»ç °ü·Ã ¹®¼­ ÀÛ¼º¡¤ÃâÆÇ, Á¦Ç° µî·Ï¡¤ÀÓ»ó½ÃÇè ½Åû, ±âŸ ¼­ºñ½º), Á¦Ç° À¯Çü(Áø´Ü, Ä¡·áÁ¦), ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ(ÀÎÇϿ콺, ¾Æ¿ô¼Ò½Ì)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Medical Device Regulatory Affairs Market to Reach US$21.0 Billion by 2030

The global market for Medical Device Regulatory Affairs estimated at US$13.1 Billion in the year 2024, is expected to reach US$21.0 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Regulatory Consulting, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$7.5 Billion by the end of the analysis period. Growth in the Legal Representation segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 13.0% CAGR

The Medical Device Regulatory Affairs market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Medical Device Regulatory Affairs Market - Key Trends & Drivers Summarized

Why Are Regulatory Affairs Becoming Central to Medical Device Commercialization?

In today’s rapidly evolving healthcare landscape, regulatory affairs have become a strategic cornerstone in the medical device industry, playing a vital role in ensuring that products meet the strict safety, efficacy, and performance standards required for market approval. As medical devices grow more complex-often integrating software, digital connectivity, and AI-the regulatory approval process has correspondingly become more intricate and time-consuming. Companies are increasingly investing in dedicated regulatory affairs teams or outsourcing expertise to ensure smooth navigation through pre-market submissions, product classifications, risk management protocols, and post-market surveillance requirements.

Regulatory bodies such as the U.S. FDA, European Medicines Agency (EMA), Japan’s PMDA, and China’s NMPA are continuously updating their frameworks to keep pace with innovation. Recent regulations like the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have introduced stricter rules on clinical evaluation, device classification, traceability, and post-market obligations. These developments have transformed regulatory affairs from a backend compliance function into a strategic partner in product development. Companies now integrate regulatory strategy early in the product lifecycle to mitigate the risk of launch delays, market withdrawals, or reputational damage. As the global medical device market expands across new geographies, regulatory harmonization and localization are becoming dual imperatives, requiring in-depth knowledge of both international standards and country-specific nuances.

How Are Technology and Data Shaping the Future of Regulatory Submissions?

Technology is reshaping regulatory affairs, bringing in a wave of digital tools and data-driven systems that enhance efficiency, accuracy, and transparency in managing submissions and compliance. Electronic submissions through platforms like FDA’s eSTAR and EMA’s EUDAMED are replacing manual documentation, reducing errors, improving timelines, and enabling easier access to regulatory data. Regulatory Information Management Systems (RIMS) are gaining popularity for tracking submission status, managing product registrations across countries, and maintaining regulatory intelligence databases. These systems are particularly valuable for companies operating in multiple jurisdictions with varying document formats, approval timelines, and surveillance requirements.

Artificial Intelligence (AI) and machine learning are beginning to find applications in regulatory affairs as well-automating literature searches, analyzing adverse event patterns, and predicting regulatory risks based on historical data. Natural Language Processing (NLP) tools are being used to extract and organize large volumes of regulatory text, enabling teams to generate submission-ready documentation more efficiently. Furthermore, cloud-based platforms are facilitating global collaboration between regulatory teams, clinical experts, and consultants, ensuring alignment throughout the lifecycle of a device. The integration of real-world evidence (RWE) and real-world data (RWD) into regulatory decision-making is also gaining momentum, with agencies beginning to accept these data types for post-market monitoring and, in some cases, approval extensions. These technological advancements are streamlining operations and allowing regulatory affairs professionals to take on more strategic and analytical roles within organizations.

Who’s Leading the Charge and How Is Globalization Influencing Regulatory Strategies?

The regulatory affairs market is expanding rapidly across all segments of the medical device industry-from multinational corporations with vast product portfolios to emerging startups bringing disruptive innovations to market. Large medtech companies are building in-house regulatory teams with global expertise to manage extensive pipelines and multiple market entries, while small and mid-sized firms are increasingly turning to specialized regulatory consultants or contract research organizations (CROs) for support. This shift toward outsourcing is especially prevalent in highly regulated markets like the EU and U.S., where navigating submissions such as 510(k), PMA, CE marking, or technical dossiers can be resource-intensive and time-sensitive.

Globalization is exerting a strong influence on regulatory strategies, as manufacturers seek access to high-growth markets in Asia-Pacific, Latin America, and the Middle East. These regions are enhancing their regulatory frameworks to match international standards while maintaining local compliance requirements-demanding a nuanced, region-specific approach. For example, China’s evolving NMPA approval process now mandates local clinical data for many devices, prompting foreign firms to collaborate with local entities. In parallel, initiatives such as the International Medical Device Regulators Forum (IMDRF) are working toward harmonizing submission formats and terminology to reduce redundancy and facilitate global approvals. In response, companies are restructuring regulatory teams to function as agile, cross-border units capable of adapting to both centralized and decentralized market models.

What’s Driving Growth in the Medical Device Regulatory Affairs Market?

The growth in the medical device regulatory affairs market is driven by several interrelated factors linked to technological innovation, regulatory tightening, and expanding global healthcare markets. First and foremost, the increasing complexity of medical devices-especially those involving software as a medical device (SaMD), AI-driven diagnostics, and combination products-necessitates deeper regulatory engagement and proactive strategy development. This complexity is further amplified by the shift from periodic submission-based compliance to continuous lifecycle monitoring, compelling companies to maintain real-time vigilance over safety signals, field performance, and labeling updates.

End-use diversification is also contributing to market growth. As non-traditional players such as digital health startups, pharma-biotech firms, and consumer tech companies enter the medical device space, they require specialized regulatory support to navigate unfamiliar regulatory landscapes. Additionally, growing patient demand for transparency and safety, combined with media scrutiny over device recalls or adverse events, is pushing firms to prioritize compliance and risk communication as central to brand credibility. On the operational side, the rise of remote audits, digital submissions, and AI-enabled regulatory technologies is improving submission accuracy and reducing review times-enhancing return on investment and driving further adoption.

Lastly, the global expansion of healthcare systems and the increasing volume of clinical trials involving devices are pushing demand for regulatory professionals with cross-functional expertise. The scarcity of skilled regulatory talent in many markets is further fueling the growth of regulatory service providers and training platforms. Together, these drivers are positioning regulatory affairs not just as a compliance function but as a vital, growth-enabling force in the medical device innovation ecosystem.

SCOPE OF STUDY:

The report analyzes the Medical Device Regulatory Affairs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services); Type (Diagnostic, Therapeutic); Service Provider (In-house, Outsource)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â